DaVita Inc. $DVA Shares Sold by Sei Investments Co.

Sei Investments Co. reduced its holdings in DaVita Inc. (NYSE:DVA) by 21.8% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 68,340 shares of the company’s stock after selling 19,053 shares during the period. Sei Investments Co.’s holdings in DaVita were worth $10,502,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Globeflex Capital L P grew its stake in DaVita by 4.9% during the 1st quarter. Globeflex Capital L P now owns 13,060 shares of the company’s stock valued at $2,007,000 after acquiring an additional 614 shares in the last quarter. Cetera Investment Advisers boosted its holdings in shares of DaVita by 8.0% during the 1st quarter. Cetera Investment Advisers now owns 8,110 shares of the company’s stock worth $1,246,000 after purchasing an additional 602 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of DaVita by 18.3% during the 1st quarter. First Trust Advisors LP now owns 37,692 shares of the company’s stock worth $5,793,000 after purchasing an additional 5,820 shares during the last quarter. Cassaday & Co Wealth Management LLC purchased a new stake in shares of DaVita in the first quarter valued at approximately $79,000. Finally, Hollencrest Capital Management increased its holdings in shares of DaVita by 5.7% in the first quarter. Hollencrest Capital Management now owns 2,789 shares of the company’s stock valued at $429,000 after purchasing an additional 150 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Performance

DVA opened at $240.00 on Friday. DaVita Inc. has a one year low of $101.00 and a one year high of $244.49. The stock has a market capitalization of $15.41 billion, a PE ratio of 22.26, a P/E/G ratio of 0.79 and a beta of 0.88. The business’s 50 day moving average price is $217.76 and its 200 day moving average price is $173.13.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. During the same quarter last year, the firm earned $2.00 earnings per share. The firm’s quarterly revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities research analysts forecast that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on DVA. Truist Financial boosted their price objective on DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Barclays raised their target price on DaVita from $194.00 to $218.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 8th. TD Cowen boosted their price target on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research report on Monday, May 11th. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. Finally, Zacks Research cut shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus price target of $216.50.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.